Print Page  Close Window

SEC Filings

OREXIGEN THERAPEUTICS, INC. filed this Form S-1/A on 04/09/2007
Entire Document

  12.01   It shall be a sufficient giving of any notice, request, report, statement, disclosure or other communication hereunder if the party giving the same shall
  (a)   hand deliver such communication; or
  (b)   mail such a communication, postage prepaid, first class, certified mail; or
  (c)   send such communication, shipping prepaid by national/international courier service
      to the party to receive such communication at the address given below, or such other address as may hereafter be designated by notice in writing by the appertaining party.
For delivery via the U.S. Postal Service
Orexigen Therapeutics, Inc.
  Cypress Bioscience, Inc.
Attn: Chief Executive Officer
  Attn: Chief Executive Officer
One Palmer Square, Suite 515
Princeton, NJ 08540
  4350 Executive Drive, Suite 325
San Diego, CA 92121
cc: (if of a legal nature)
Biotech Law Associates, P.C.
  Cooley Godward LLP
Attn: Douglas A. Branch
800 Research Parkway, Suite 310
Oklahoma City, OK 73104
  Attn: Kay Chandler
4410 Eastgate Mall
San Diego, CA 92121
  12.02   DATE OF NOTICE. The date of giving any such notice, request, report, statement, disclosure or other communications, and the date of making any payment hereunder required (provided such payment is received), shall be the actual date of receipt.
  13.01   This AGREEMENT shall be binding upon and inure to the benefit of the respective permitted successors and assigns of the parties hereto. However, neither this AGREEMENT nor any rights or obligations hereunder may be assigned or otherwise transferred by either party without the prior written approval of the other party, such approval not to be unreasonably withheld; provided that either party may assign this AGREEMENT and its rights and obligations hereunder without the other party’s consent in connection with the transfer or sale of all or substantially all of the business of such party to which this AGREEMENT relates to a THIRD PARTY, whether by merger, sale of stock, sale of assets or otherwise. In the event of such transaction, however, intellectual

- 27 -